+

WO1998030204A1 - Preconcentres pharmaceutiques en microemulsions, a base de cyclosporines - Google Patents

Preconcentres pharmaceutiques en microemulsions, a base de cyclosporines Download PDF

Info

Publication number
WO1998030204A1
WO1998030204A1 PCT/CA1998/000023 CA9800023W WO9830204A1 WO 1998030204 A1 WO1998030204 A1 WO 1998030204A1 CA 9800023 W CA9800023 W CA 9800023W WO 9830204 A1 WO9830204 A1 WO 9830204A1
Authority
WO
WIPO (PCT)
Prior art keywords
solvent
hydrophobic
composition according
solvent system
tocopherols
Prior art date
Application number
PCT/CA1998/000023
Other languages
English (en)
Inventor
Bernard Charles Sherman
Original Assignee
Bernard Charles Sherman
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bernard Charles Sherman filed Critical Bernard Charles Sherman
Publication of WO1998030204A1 publication Critical patent/WO1998030204A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers

Definitions

  • the invention is directed to pharmaceutical compositions which facilitate the administration of cyclosporins.
  • cyclosporin refers to any member of a class of nonpolar polypeptides, as defined in the Merck Index, Twelfth Edition.
  • One such cyclosporin is cyclosporin A, also known as “cyclosporine” and hereinafter referred to as “cyclosporine”, known to be therapeutically active as an immunosuppressant.
  • Cyclosporins are hydrophobic and have low solubility in aqueous media. This makes it difficult to design pharmaceutical compositions (i.e. dosage forms) comprising cyclosporins which exhibit satisfactory absorption into systemic circulation after oral administration, or absorption into the target tissue upon topical administration.
  • the cyclosporin can be dissolved in an organic solvent (e.g. ethanol or propyle ⁇ e glycol), but if the solvent is water-miscible, when the composition is mixed with gastrointestinal fluid or other aqueous medium, the cyclosporin will precipitate.
  • an organic solvent e.g. ethanol or propyle ⁇ e glycol
  • U.S. patent 4388307 discloses compositions comprising cyclosporine in an emulsion preconcentrate that is not water-miscible, but forms an emulsion upon being mixed into gastrointestinal fluids.
  • a commercial product that has been sold under the trademark "Sandimmune” is made according to U.S. patent 4388307, and, more specifically, comprises cyclosporine dissolved in a solvent system comprising ethanol, a vegetable oil and a surfactant.
  • ethanol a solvent system comprising ethanol, a vegetable oil and a surfactant.
  • this composition was superior to previously known compositions, it still exhibits absorption that is less than the maximum possible and is variable.
  • the use of ethanol has disadvantages, as ethanol is volatile, and the capsules of Sandimmune must be individually packaged in metallic pouches to avoid evaporation of the ethanol.
  • U.S. patent 5342625 discloses compositions that are said to be superior in certain respects to the compositions of U.S. patent 4388307.
  • the compositions of U.S. patent 5342625 comprise, in addition to the cyclosporin, a hydrophilic phase, a lipophilic (i.e. hydrophobic) phase and a surfactant.
  • the hydrophilic phase is either propylene glycol or a pharmaceutically acceptable alkyl or tetrahydrofurfuryl di- or partial-ether of a low molecular weight mono- or poly-oxy- alkanediol.
  • the lipophilic phase comprises a solvent which is non-miscible with the hydrophilic phase, and is preferably a fatty acid triglyceride.
  • compositions according to U.S. patent 5342625 when added to water, disperse into emulsions with droplet size of less than 2000A, which is smaller than that obtained with prior art compositions, thus leading to improved absorption.
  • Emulsions with droplet size of less than 2000A are defined as "microemuisions”.
  • Compositions that, upon addition to water, disperse into microemuisions are called “microemulsion preconcentrates”.
  • a composition made according to the disclosure of U.S. patent 5342625 is now marketed under the trademark "Neoral", in the form of both a soft gelatin capsule containing the microemulsion preconcentrate, and an oral liquid which is a ° microemulsion preconcentrate intended to be diluted into an aqueous drink before ingestion.
  • the labelling indicates that the "Neoral" emulsion preconcentrate comprises cyclosporine dissolved in 10 ethanol and propylene glycol as hydrophilic solvents, corn oil as lipophilic (hydrophobic) solvent, and polyoxyl 40 hydrogenated castor oil as surfactant. It also contains dl-alpha-tocoperol at a level of about one percent by weight as antioxidant, apparently to prevent oxidation of the corn oil.
  • Ethanol is volatile, so that the soft gelatin capsules have to be packaged individually in metallic pouches to prevent evaporation of the ethanol.
  • Ethanol contributes to an undesirable taste of the microemulsion preconcentrate, so that, even after dilution into a sweetened drink, there is still a somewhat unpleasant taste.
  • the concentration of cyclosporine is limited to about 100 mg per mL so that a soft gelatin capsule containing 100 mg of cyclosporine is larger than desirable and difficult to swallow.
  • compositions 30 in the form of microemulsion preconcentrates in which the principal solvent for the cyclosporin is an alcohol which is selected from alcohols having a boiling point above 100°C and a solubility in water of under 10 g per 100 g at 20°C. Such alcohols are referred to as hydrophobic alcohols.
  • Preferred hydrophobic alcohols within the scope of the disclosure of W094/25068, are saturated alkyl alcohols having 8 to 14 carbon atoms per molecule, including 1-octyl, 2-octyl, 1-decyl, 1-dodecyl and 1-tetradecyl alcohols.
  • Preferred surfactants for use along with the hydrophobic alcohol are polyoxethylene glycolated natural or hydrogenated vegetable oils.
  • New Zealand Patent Application No. 280689 discloses improved microemulsion preconcentrates in which a cyclosporin is dissolved in a solvent system comprising a hydrophobic component, a hydrophilic component and a surfactant, wherein the hydrophobic component is selected from tocol, tocopherols and tocotrienols, and derivatives thereof.
  • the preferred surfactants are again polyoxyethylene glycolated natural or hydrogenated vegetable oils.
  • compositions of International Publication Number W094/25068 and New Zealand Patent Application No. 280689 provide certain advantages relative to Neoral, they still have certain limitations. Specifically, it has been found that, despite the advantages of compositions within the scope of these disclosures, it is difficult to achieve a microemulsion with droplet size as small as is achieved with Neoral, with the result that it is difficult to achieve, upon oral administration, absorption into systemic circulation as good as that achieved with Neoral.
  • the quantity of the preferred surfactant i.e. a polyoxyethylene glycolated natural or hydrogenated vegetable oil
  • the quantity of the preferred surfactant i.e. a polyoxyethylene glycolated natural or hydrogenated vegetable oil
  • the quantity of the preferred surfactant i.e. a polyoxyethylene glycolated natural or hydrogenated vegetable oil
  • solvent system as used herein is to be understood to mean the carrier in which the drug (i.e. a cyclosporin) is dissolved.
  • the solvent system may be a single solvent or a combination or a mixture of ingredients included as
  • both International Publication W094/25068 and New Zealand Patent Application No. 280689 disclose that polyoxyethylene glycolated 25 natural or hydrogenated vegetable oils are preferred surfactants.
  • one aspect of the invention is the use of a solvent system comprising two hydrophobic solvents, one of which is a hydrophobic alcohol and the second of which is selected from tocol, tocopherols and tocotrienols and derivatives thereof.
  • a second aspect of the invention is the use of a combination of two surfactants, one of which is a polyoxyethylene glycolated natural or hydrogenated vegetable oil and the second of which is another water- soluble nonionic surfactant.
  • the invention is a microemulsion preconcentrate comprising a cyclosporin dissolved in a solvent system, wherein said solvent system further comprises at least one hydrophobic solvent and at least one surfactant, and wherein either:
  • the solvent system comprises two hydrophobic solvents, one of which is a hydrophobic alcohol and the second of which is selected from tocol, tocopherols, tocotrienols, and derivatives thereof, or
  • the solvent system comprises two water-soluble nonionic surfactants, one of which is a polyoxyethylene glycolated natural or hydrogenated vegetable oil.
  • a microemulsion preconcentrate comprising a cyclosporin must contain at least one hydrophobic solvent, at least one surfactant, also preferably at least one hydrophilic solvent.
  • a hydrophobic solvent is needed because, if the cyclosporin is dissolved in only a hydrophilic solvent, then when the composition is mixed into an aqueous medium, the hydrophilic solvent will dissolve in the water, causing precipitation of the cyclosporin.
  • a surfactant is needed to enable the composition (i.e. the microemulsion preconcentrate) to disperse into a microemulsion when added to water.
  • the solvents used in the composition have adequate capacity to dissolve the cyclosporin and to keep it dissolved without precipitation during long term storage.
  • hydrophobic solvents are not very good solvents for cyclosporine. Accordingly, if only hydrophobic solvents are used, the quantity needed is larger than desirable. The quantity can be decreased by including in the composition some quantity of a hydrophilic solvent that is a better solvent for the cyclosporin.
  • Ethanol can be used as the hydrophilic solvent, but ethanol has the disadvantage of being volatile.
  • Preferred hydrophilic solvents that are less volatile are propylene glycol, propylene carbonate, benzyl alcohol, and low molecular weight polyethylene glycols in the range of less than about 1000.
  • one aspect of the invention is the use of a solvent system comprising two hydrophobic solvents, one of which is a hydrophobic alcohol, and the second of which is selected from tocol, tocopherols, and tocotrienols and derivatives thereof.
  • hydrophobic alcohol as used hereinafter shall be understood as meaning a monoalcohol having a solubility in water of under 5 g per 100 g at
  • Preferred hydrophobic alcohols are saturated alkyl alcohols having from 8 to 16 carbon atoms per molecule.
  • 1-dodecyl alcohol also known as lauryl alcohol
  • 1- tetradecyl alcohol also known as myristyl alcohol
  • tocopherols as used herein is to be understood to mean any one of or a mixture of any of the compounds which can be regarded as a substituted tocol and is identified as a type of tocopherol in the Merck Index Twelfth Edition at entry numbers 9632 to 9638 inclusive and entry number 10159, specifically including alpha-, beta-, delta- and gamma-tocopherol.
  • Alpha-tocopherol is also known as Vitamin E.
  • tocotrienol as used herein shall be understood to mean any one of or a mixture of alpha-, beta-, delta- and gamma-tocotrienol. Tocotrienols are similar to tocopherols but have an unsaturated side chain consisting of three double bonds.
  • derivative will be understood to mean any compound that can be formed by a reaction with any compound selected from tocol, tocopherols and tocotrienols. Derivatives will thus include, for example, tocol acetate, and alpha- tocopheryl acetate. Some or all of tocol, the tocopherols and the tocotrienols, and derivatives thereof are available as different stereoisomers, and it will be understood that the different stereoisomers or mixtures thereof are included within the definition.
  • tocopherols From among tocol, tocopherols, tocotrienols and derivatives thereof the preferred choices are alpha-tocopherol and natural mixed tocopherols.
  • natural mixed tocopherols are available, for example, as products sold under the tradenames Tenox GT-2 by Eastman Chemical Products Inc. and Covi-Ox T-70 by Henkel Corporation.
  • Tenox GT-2 and Covi-Ox T-70 both are comprised of about 70% total tocopherols and 30% vegetable oil.
  • the total tocopherol content in these products is made up of approximately 12% to 14% d-alpha, 62% to 65% d- gamma, 23% to 24% d-delta and 1 % d-beta.
  • a second aspect of the invention is the use of a combination of two surfactants, the first of which is a polyoxyethylene glycolated natural or hydrogenated vegetable oil; for example, polyoxyethylene glycolated natural or hydrogenated castor oil. Particularly suitable are the products designated in the
  • the second surfactant is another water-soluble nonionic surfactant.
  • Preferred as the second surfactant are polyoxyethylene-sorbitan-fatty acid esters; e.g. mono- and tri-lauryl, palmityl, stearyl and oleyl esters; e.g. products of the type known as polysorbates and commonly available under the tradename "Tween”.
  • polyoxyethylene 20 sorbitan monolaurate which is also known as polysorbate 20. While the two aspects of the invention may be used independently of each other, it is preferred to use them together.
  • Preferred compositions are thus compositions which comprise ail of the following:
  • compositions in accordance with the invention may also contain other ingredients.
  • the composition may include, in addition to the foregoing, one or more other ingredients that are included as diluents, thickening agents, anti- oxidants, flavouring agents, and so forth.
  • compositions in accordance with the invention may be liquids at ambient temperature or they may be solids prepared, for example, by use of one or more ingredients with melting point above ambient temperature.
  • the ingredients may be blended at a temperature above the melting point and then used to fill capsules while still molten, or cooled to form solids.
  • the solids may be ground into granules or powder for further processing; for example, filling capsules or manufacture of tablets.
  • composition is a solid at room temperature
  • this may be accomplished by adding a further ingredient with a relatively high melting point, such as, for example, polyethylene glycol with average molecular weight of above 1000.
  • a further ingredient with a relatively high melting point such as, for example, polyethylene glycol with average molecular weight of above 1000.
  • Capsules or tablets may be further processed by applying coatings thereto.
  • compositions in accordance with the invention may comprise dosage forms for 5 direct administration as microemulsion preconcentrates.
  • the microemulsion preconcentrate may be directly used as liquid for oral ingestion, parenteral use, or topical application or it may be encapsulated into gelatin capsules for oral ingestion.
  • the present invention also provides pharmaceutical compositions in which the microemulsion preconcentrate is further processed into a microemulsion.
  • microemuisions obtained, e.g. by diluting a microemulsion preconcentrate with water or other aqueous medium (for example, a sweetened or flavoured preparation for
  • compositions comprising a microemulsion preconcentrate, a thickening agent, and water will provide an aqueous microemulsion in gel, paste, cream or like form.
  • compositions in accordance with the present invention may be employed for administration in any appropriate manner and form; e.g. orally, as liquids or granules or in unit dosage form, for example in hard or soft gelatin encapsulated form, parenterally or topically; e.g. for application to the skin; for example in the form of a cream, ⁇ paste, lotion, gel, ointment, poultice, cataplasm, plaster, dermal patch, powder, topically applicable spray, or the like, or for ophthalmic application; for example in the form of an eye-drop, lotion or gel formulation.
  • Readily flowable forms may also be employed; e.g.
  • compositions in accordance with the invention 0 are, however, primarily intended for oral or topical application, including application to the skin or eyes.
  • the relative proportion of the cyclosporin and other ingredients in the compositions of the invention will, of course, vary considerably depending on the particular type of composition concerned; e.g. whether it is a microemulsion preconcentrate or microemulsion, the route of administration, and so forth.
  • the relative proportions will also vary depending on the particular ingredients employed and the desired physical characteristics of the composition, e.g. in the case of a composition for topical use, whether this is to be a free flowing liquid or a paste. Determination of workable proportions in any particular instance will generally be within the capability of persons skilled in the art.
  • the ingredients were weighed into a test tube in the proportions shown, the test tubes and contents were warmed to 100°C in a water bath, and then the test tubes were shaken until the contents of each tube were interdissolved to form a clear solution.
  • the transmittance is that of an emulsion or microemulsion made by dispersing 1 g of the composition in 20 mL of warm water. It can be seen that the transmittance is only about 65% when either 1-tetradecyl alcohol or Covi-Ox- T-70 is used alone as hydrophobic solvent, but the transmittance improves substantially in examples 2 to 5, when a combination of the two is used.
  • the high opacity (low transmittance) obtained with a dispersion of the composition of example 12 in water shows that Polysorbate 20 when used alone js ineffective as a surfactant in the composition.
  • the higher transmittance obtained with example 7 shows that Cremophor RH40 (Polyoxyl 40 Hydrogenated Castor Oil) when used alone as the surfactant is much superior to Polysorbate 20.
  • Examples 8 and 9 demonstrate that an even higher transmittance and thus a finer microemulsion can be obtained by using a combination of the two surfactants instead of using Polyoxyl 40 Hydrogenated Castor Oil alone.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention a pour objet un préconcentré en microémulsion à base de cyclosporines, dissous dans un système de solvant. Ce système de solvant comprend deux solvants hydrophobes, dont un est un alcool hydrophobe et le deuxième est sélectionné parmi du tocol, des tocophérols, des tocotriénols, et des dérivés de ces derniers, ou ce système de solvant comprend deux tensio-actifs dont un est une huile végétale hydrogénée ou naturelle glycolatée de polyoxyéthylène, et le deuxième est un autre tensio-actif non ionique soluble à l'eau.
PCT/CA1998/000023 1997-01-13 1998-01-13 Preconcentres pharmaceutiques en microemulsions, a base de cyclosporines WO1998030204A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NZ314060 1997-01-13
NZ31406097A NZ314060A (en) 1997-01-13 1997-01-13 Pharmaceutical microemulsion preconcentrate comprising cyclosporin dissolved in a solvent system comprising hydrophobic solvent(s) and surfactant(s)

Publications (1)

Publication Number Publication Date
WO1998030204A1 true WO1998030204A1 (fr) 1998-07-16

Family

ID=19926106

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA1998/000023 WO1998030204A1 (fr) 1997-01-13 1998-01-13 Preconcentres pharmaceutiques en microemulsions, a base de cyclosporines

Country Status (2)

Country Link
NZ (1) NZ314060A (fr)
WO (1) WO1998030204A1 (fr)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000071163A1 (fr) * 1999-05-24 2000-11-30 Sonus Pharmaceuticals, Inc. Excipient en emulsion pour medicaments faiblement solubles
US6458373B1 (en) 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
WO2002026208A3 (fr) * 2000-09-27 2003-01-23 Sonus Pharma Inc Excipient emulsionne pour medicaments a faible solubilite
US6727280B2 (en) 1997-01-07 2004-04-27 Sonus Pharmaceuticals, Inc. Method for treating colorectal carcinoma using a taxane/tocopherol formulation
US7026290B1 (en) 1998-12-30 2006-04-11 Dexcel Ltd. Dispersible concentrate for the delivery of cyclosprin
US7030155B2 (en) 1998-06-05 2006-04-18 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
US7060672B2 (en) 2001-10-19 2006-06-13 Isotechnika, Inc. Cyclosporin analog formulations
US8575147B2 (en) 1999-02-16 2013-11-05 Novartis Ag Spontaneously dispersible N-benzoyl staurosporine compositions

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6219512A (ja) * 1985-07-17 1987-01-28 Shiseido Co Ltd 養毛剤
GB2218334A (en) * 1988-05-13 1989-11-15 Sandoz Ltd Cyclosporin compositions for topical application
EP0711550A1 (fr) * 1994-11-09 1996-05-15 Hanmi Pharm. Ind. Co., Ltd. Compositions pour capsule molle à base de cyclosporine
US5589455A (en) * 1994-12-28 1996-12-31 Hanmi Pharm. Ind. Co., Ltd. Cyclosporin-containing soft capsule compositions

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6219512A (ja) * 1985-07-17 1987-01-28 Shiseido Co Ltd 養毛剤
GB2218334A (en) * 1988-05-13 1989-11-15 Sandoz Ltd Cyclosporin compositions for topical application
EP0711550A1 (fr) * 1994-11-09 1996-05-15 Hanmi Pharm. Ind. Co., Ltd. Compositions pour capsule molle à base de cyclosporine
US5589455A (en) * 1994-12-28 1996-12-31 Hanmi Pharm. Ind. Co., Ltd. Cyclosporin-containing soft capsule compositions

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6982282B2 (en) 1997-01-07 2006-01-03 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
US6458373B1 (en) 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
US6660286B1 (en) 1997-01-07 2003-12-09 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
US6667048B1 (en) 1997-01-07 2003-12-23 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
US6727280B2 (en) 1997-01-07 2004-04-27 Sonus Pharmaceuticals, Inc. Method for treating colorectal carcinoma using a taxane/tocopherol formulation
US7030155B2 (en) 1998-06-05 2006-04-18 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
US7026290B1 (en) 1998-12-30 2006-04-11 Dexcel Ltd. Dispersible concentrate for the delivery of cyclosprin
US8575147B2 (en) 1999-02-16 2013-11-05 Novartis Ag Spontaneously dispersible N-benzoyl staurosporine compositions
US8722664B2 (en) 1999-02-16 2014-05-13 Novartis Ag Spontaneously dispersible N-benzoyl staurosporine compositions
WO2000071163A1 (fr) * 1999-05-24 2000-11-30 Sonus Pharmaceuticals, Inc. Excipient en emulsion pour medicaments faiblement solubles
WO2002026208A3 (fr) * 2000-09-27 2003-01-23 Sonus Pharma Inc Excipient emulsionne pour medicaments a faible solubilite
US7060672B2 (en) 2001-10-19 2006-06-13 Isotechnika, Inc. Cyclosporin analog formulations
US7429562B2 (en) 2001-10-19 2008-09-30 Isotechnika Inc. Cyclosporin analog formulations

Also Published As

Publication number Publication date
NZ314060A (en) 1997-08-22

Similar Documents

Publication Publication Date Title
US5998365A (en) Microemulsion preconcentrates comprising cyclosporins
EP0696920B1 (fr) Compositions ameliorees, pharmaceutiquement acceptables, contenant un alcool et un medicament hydrophobe
US6197335B1 (en) Solid pharmaceutical compositions comprising a cyclosporin and an anionic surfactant
US5798333A (en) Water-soluble concentrates containing cyclosporins
US5958876A (en) Cyclosporin-containing pharmaceutical compositions
CA2471241A1 (fr) Compositions pharmaceutiques comprenant une cyclosporine, un tensioactif hydrophile et un tensioactif lipophile
EP1413297B1 (fr) Preparations contenant de la cyclosporine
US6159933A (en) Emulsion preconcentrate comprising a cyclosporin, propylene carbonate, and glycerides
WO1998030204A1 (fr) Preconcentres pharmaceutiques en microemulsions, a base de cyclosporines
US6258783B1 (en) Emulsion preconcentrate comprising a cyclosporin and acetylated monoglyceride
AU741923B2 (en) Pharmaceutical compositions
MXPA98003393A (en) Preconcentrated emulsion comprising a cyclosporine and monoglycerid acetyl
WO1999045946A1 (fr) Preconcentres d'emulsions comprenant une cyclosporine et des glycerides
NZ314701A (en) Pharmaceutical compositions comprising a cyclosporin dissolved in propylene carbonate, a lipophilic solvent comprising glycerides and a surfactant
AU722285B2 (en) Cyclosporin-containing soft capsule preparations
AU753018B2 (en) Cyclosporin-containing soft capsule preparations
NZ270549A (en) Pharmaceutical composition comprising a cyclosporin dissolved in a solvent system comprising propylene glycol, a monoalcohol and a surfactant
CA2185600A1 (fr) Concentres hydrosolubles renfermant des cyclosporines

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): CA

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载